Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology (Q37757640)

22 August 2017

Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology (English)

1 reference

22 August 2017

1 reference

Mark H Einstein

1

1 reference

22 August 2017

Mark G Martens

2

1 reference

22 August 2017

Francisco A R Garcia

3

1 reference

22 August 2017

Daron G Ferris

4

1 reference

22 August 2017

Amy L Mitchell

5

1 reference

22 August 2017

Stephen P Day

6

1 reference

22 August 2017

Marilyn C Olson

7

1 reference

22 August 2017

language of work or name

English

0 references

publication date

21 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

118

1 reference

22 August 2017

116-122

1 reference

22 August 2017

2

1 reference

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Clinical utility of HPV genotyping

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

American Cancer Society guideline for the early detection of cervical neoplasia and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

The 2001 Bethesda System: terminology for reporting results of cervical cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Detection of high-risk papillomavirus DNA with commercial invader-technology-based analyte-specific reagents following automated extraction of DNA from cervical brushings in ThinPrep media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Human papillomavirus genotype specificity of hybrid capture 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Analytical performance of the Investigational Use Only Cervista HPV HR test as determined by a multi-center study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

From the National Institutes of Health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

A comparison of two methods to determine the presence of high-risk HPV cervical infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

A review of human carcinogens--Part B: biological agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.04.013

10.1016/J.YGYNO.2010.04.013

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference